Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies

Antioxidants and Redox Signaling

Volumn 23, Issue 1, 2015, Pages 1-14

  Le Bescont, Aurore ^a   Vitte, Anne Laure ^a   Debernardi, Alexandra ^a   Curtet, Sandrine ^a   Buchou, Thierry ^a   Vayr, Jessica ^a   De Reyniès, Aurélien ^b   Ito, Akihiro ^c   Guardiola, Philippe ^d   Brambilla, Christian ^a   Yoshida, Minoru ^c   Brambilla, Elisabeth ^a   Rousseaux, Sophie ^a   Khochbin, Saadi ^a  

^a INSERM   (France)

^b Programme Cartes d'Identite des Tumeurs   (France)

^c RIKEN   (Japan)

^d UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROLACTIN RECEPTOR; SIGNAL PEPTIDE; TRICHOSTATIN A; PROLACTIN; TUMOR MARKER;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER PROGNOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE ACTIVITY; EXPRESSED SEQUENCE TAG; FATALITY; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; CARCINOMA, NON-SMALL-CELL LUNG; COHORT ANALYSIS; FEMALE; GENETICS; LUNG NEOPLASMS; METABOLISM; PREGNANCY; PROGNOSIS; SIGNAL TRANSDUCTION;

ADULT; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREGNANCY; PROGNOSIS; PROLACTIN; RECEPTORS, PROLACTIN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84934915947     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5581     Document Type: Article

References (39)

1. Axelsen JB, Lotem J, Sachs L, and Domany E. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci U S A 104: 13122-13127, 2007.
2. Bole-Feysot C, Goffin V, Edery M, Binart N, and Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19: 225-268, 1998.
3. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, and Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622, 2009.
4. Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, Jongeneel CV, Old LJ, and Simpson AJ. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A 102: 7940-7945, 2005.
5. de Giorgio A, Krell J, Harding V, Stebbing J, and Castellano L. Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN. Mol Cell Biol 33: 3976-3982, 2013.
6. Doyle JM, Gao J, Wang J, Yang M, and Potts PR. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 39: 963-974, 2010.
7. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, and Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 281: 15215-15226, 2006.
8. Emadali A, Rousseaux S, Bruder-Costa J, Rome C, Duley S, Hamaidia S, Betton P, Debernardi A, Leroux D, Bernay B, Kieffer-Jaquinod S, Combes F, Ferri E, McKenna CE, Petosa C, Bruley C, Garin J, Ferro M, Gressin R, Callanan MB, and Khochbin S. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med 5: 1180-1195, 2013.
9. Feichtinger J, Aldeailej I, Anderson R, Almutairi M, Almatrafi A, Alsiwiehri N, Griffiths K, Stuart N, Wakeman JA, Larcombe L, and McFarlane RJ. Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes. Oncotarget 3: 843-853, 2012.
10. Fernandez I, Touraine P, and Goffin V. Prolactin and human tumourogenesis. J Neuroendocrinol 22: 771-777, 2010.
11. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, and Bradner JE. Selective inhibition of BET bromodomains. Nature 468: 1067-1073, 2010.
12. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 7: 247-265, 2012.
13. Gandhi L and Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 4: 631-638, 2006.
14. Gaucher J, Boussouar F, Montellier E, Curtet S, Buchou T, Bertrand S, Hery P, Jounier S, Depaux A, Vitte AL, Guardiola P, Pernet K, Debernardi A, Lopez F, Holota H, Imbert J, Wolgemuth DJ, Gerard M, Rousseaux S, and Khochbin S. Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J 31: 3809-3820, 2012.
15. Gerlo S, Davis JR, Mager DL, and Kooijman R. Prolactin in man: a tale of two promoters. Bioessays 28: 1051-1055, 2006.
16. Goffin V and Carter-Su C. Meeting report: the 2012 FASEB Science Research Conference "The growth hormone/prolactin family in biology and disease" A novel biannual rendez-vous in the endocrinology landscape. Pediatr Endocrinol Rev 10: 243-245, 2012.
17. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2013.
18. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L, Bilban M, Zielinski CC, Drach J, and Zochbauer-Muller S. Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 68: 44-54, 2008.
19. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, and Hide W. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 105: 20422-20427, 2008.
20. Ignacak A, Kasztelnik M, Sliwa T, Korbut RA, Rajda K, and Guzik TJ. Prolactin - not only lactotrophin. A "new" view of the "old" hormone. J Physiol Pharmacol 63: 435-443, 2012.
21. Janic A, Mendizabal L, Llamazares S, Rossell D, and Gonzalez C. Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Science 330: 1824-1827, 2011.
22. Jazirehi AR. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 21: 805-813, 2010.
23. Lotem J, Netanely D, Domany E, and Sachs L. Human cancers overexpress genes that are specific to a variety of normal human tissues. Proc Natl Acad Sci U S A 102: 18556-18561, 2005.
24. Lotem J and Sachs L. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 25: 7663-7672, 2006.
25. Mathieu R, Evrard B, Fromont G, Rioux-Leclercq N, Godet J, Cathelineau X, Guille F, Primig M, and Chalmel F. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness. Prostate 73: 1103-1114, 2013.
26. Mehnert JM and Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 13: 23-29, 2007.
27. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, and Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 103: 11160-11165, 2006.
28. Montellier E, Boussouar F, Rousseaux S, Zhang K, Buchou T, Fenaille F, Shiota H, Debernardi A, Hery P, Curtet S, Jamshidikia M, Barral S, Holota H, Bergon A, Lopez F, Guardiola P, Pernet K, Imbert J, Petosa C, Tan M, Zhao Y, Gerard M, and Khochbin S. Chromatin-to-nucleoprotamine transition is controlled by the histone H2B variant TH2B. Genes Dev 27: 1680-1692, 2013.
29. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, Caron C, Kimura H, Rousseaux S, Cole PA, Panne D, French CA, and Khochbin S. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J 29: 2943-2952, 2010.
30. Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, Laffaire J, de Reynies A, Beer DG, Timsit JF, Brambilla C, Brambilla E, and Khochbin S. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 5: 186ra66, 2013.
31. Rousseaux S, Wang J, and Khochbin S. Cancer hallmarks sustained by ectopic activations of placenta/male germline genes. Cell Cycle 12: 2331-2332, 2013.
32. Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, and French CA. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 71: 2686-2696, 2011.
33. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, and Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27: 4784-4795, 2007.
34. Shen H and Laird PW. Interplay between the cancer genome and epigenome. Cell 153: 38-55, 2013.
35. van Meerbeeck JP, Fennell DA, and De Ruysscher DK. Small-cell lung cancer. Lancet 378: 1741-1755, 2011.
36. Wang J, Emadali A, Le Bescont A, Callanan M, Rousseaux S, and Khochbin S. Induced malignant genome reprogramming in somatic cells by testis-specific factors. Biochim Biophys Acta 1809: 221-225, 2011.
37. Wang J, Rousseaux S, and Khochbin S. Sustaining cancer through addictive ectopic gene activation. Curr Opin Oncol 26: 73-77, 2013.
38. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M, and Longley BJ. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 127: 267-275, 2007.
39. Yoo YG, Hayashi M, Christensen J, and Huang LE. An essential role of the HIF-1alpha-c-Myc axis in malignant progression. Ann N Y Acad Sci 1177: 198-204, 2009.